clude Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases (NIAID); Erik De Clercq, M.D., Ph.D., chairman, Department of Microbiology and Immunology, Medical School at the Catholic University of Leuven; Axel Ullrich, Ph.D., director, Department of Molecular Biology, Max Planck Institute of Biochemistry in Germany; Professor Marc Feldmann, FMedSci, FAA, FRS, and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS, of the Kennedy Institute of Rheumatology, Imperial College London; and Craig Mello, Ph.D., Nobel Laureate, of the Howard Hughes Medical Institute and University of Massachusetts Medical School.
"Scientists across the globe work tirelessly to achieve significant and lasting contributions to improving health and well being," said Harlan Weisman, M.D., chief science and technology officer, Medical Devices & Diagnostics, Johnson & Johnson. "In acknowledging and rewarding those contributions, The Dr. Paul Janssen Award inspires us all to embody the scientific passion, compassion and leadership for which Dr. Paul was so well loved and respected."
Beyond the passion and creativity Dr. Paul demonstrated in the laboratory, he also inspired and mentored many young scientific leaders who went on to great achievements in addressing medical need.
"As in past years, we look forward to selecting a 2012 Dr. Paul Janssen Award winner from among the nominations of worthy individuals in research institutions and companies around the world, who has significantly improved human health through dedication to the advancement of science and medicine," said Craig Mello, Ph.D., Professor, Program in Molecular Medicine, University of Massachusetts Medical School and 2012 chair of the Dr. Paul Janssen Award Selection Committee.
The 2012 Dr. Paul Janssen Award winner will be announced in spring 2012.
About The Dr. Paul Janssen Award for Biomedical Research
Established by Johnson & Johnson
'/>"/>
SOURCE Johnson & Johnson Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine technology :1.
Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.2.
Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com3.
Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division4.
Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research5.
Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease6.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets7.
Record Breaking $327 Million Verdict Announced in Janssen Case8.
MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness9.
Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health10.
Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations11.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT